Ignite Creation Date:
2025-12-24 @ 1:43 PM
Ignite Modification Date:
2026-02-24 @ 8:26 AM
Study NCT ID:
NCT02172495
Status:
COMPLETED
Last Update Posted:
2018-08-31
First Post:
2014-06-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice
Sponsor:
Boehringer Ingelheim
Organization:
Study Overview
Official Title:
Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: